Work

Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer

Year: 2018

Type: conference-abstract

Source: European Urology Supplements

DOI: 10.1016/s1569-9056(18)30946-1

Authors: A. Bamias, M. Van Der Heijden, R. De Wit, A. Fléchon, H. Nishiyama, D. Castellano, A. Drakaki, N. Matsubara, A. Liepa, A. Zimmermann, K. Bell-Mcguinn, O. Hamid, D. Petrylak, T. Powles, A. Necchi

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2791742372

Cites:

Cited by:

Related to: 10